Published on
March 18, 2026
- 15:00 GMT
FDA Grants NeuroGenesis Bio RMAT Designation for NG01 for Treatment of Secondary Progressive Multiple Sclerosis
RMAT designation is based on promising Phase 2 clinical data demonstrating NG01’s potential to reduce disability and improve function in patients with PMS. LAFAYETTE, CA, UNITED STATES, March 18, 2026 /EINPresswire.com/ -- NeuroGenesis Bio Announces U.S …
Distribution channels:
Healthcare & Pharmaceuticals Industry
...
